anoth smash hit cgm demand remain robust
almost rais revenu guidanc familiar
topic price competit rule much discuss
littl new either front view revenu expect go
toward higher oper expens compani invest new market
verili product line extens remain concern
price pressur could ariseperhap suddenlybut also may occur
year frankli havent figur work predict
insur may push price due competit price lower
remain neutral feel way elimin estim risk
believ share move higher price fear play
cgm good medicin use mdi diabet
patient adopt seem remain strong sign abat
continu march toward pharmaci channel management call
recent win pharmaci coverag benefit major
nation payor note medicar funnel remain solid
gross margin pressur quarter spend
infrastructur doubl capac end year howev
climb toward end benefit low-cost
transmitt kick recent shift reduc cost staff
call center philippin reportedli gone smoothli
product pipelin remain track late earli
launch product one-piec fulli dispos wearabl
small form factor appear remain top prioriti
pipelin discuss dec analyst day plan
enter new market like gestat diabet in-hospit cgm
hope learn opportun develop
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
handili beat consensu expect top sale
estim gross margin bp lower
project compani spend increas manufactur capac year
oper expens higher model spend
compani report non-gaap lp cent better
revis model strong sale beat updat guidanc
increas forecast sensor revenu tweak transmitt
receiv sale reflect trend quarter increas outlook
patient volum also increas sale estim outyear
model top end new revenu guidanc rang
incom statement tweak gross margin cadenc account
manag commentari impact manufactur capac increas
reduc gross margin forecast stronger
margin remain
model non-gaap ep prior
actualsbtig estimate variancetot revenu net incom spend spend opex spend marginnmnmnmsourc btig estim compani filingsvari
rate neutral believ current multipl
estim ntm ev/sal expens given potenti price pressur
face increas competit valuat seem support
mani investor risk rate includ competit increas
spend chang revenu growth rate fda product recal
reimburs price pressur
bpsebit bp btig estim compani filingsnewold changentm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr ptpricemarket cap bev/salescagrev/gross profit
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
